EMA Awards Orphan Drug Status to Pegtarazimod for GVHD Treatment
The European Medicines Agency (EMA) has officially granted orphan drug designation to pegtarazimod (RLS-0071) for the treatment of patients suffering from graft-versus-host disease (GVHD). This decision follows promising data from…